

November 15, 2021

**BAUDAX BIO**<sup>®</sup>

# **Baudax Bio to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference**

MALVERN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today announced Gerri Henwood, the Company's President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held November 29 – December 2, 2021.

The fireside chat will be made available for on-demand listening beginning Monday, November 22, 2021 at 10:00 a.m. Eastern Time and may be accessed on the "Events" page within the investors section of the Baudax Bio website at <https://www.baudaxbio.com/news-and-investors>. A replay will be available on the Baudax Bio website for a period of 30 days following the event.

## **About Baudax Bio**

Baudax Bio is a pharmaceutical company focused on commercializing and developing innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs. For more information, please visit [www.baudaxbio.com](http://www.baudaxbio.com).

## **CONTACT:**

### **Investor Relations Contact:**

Argot Partners  
Sam Martin / Claudia Styslinger  
(212) 600-1902  
[baudaxbio@argotpartners.com](mailto:baudaxbio@argotpartners.com)

### **Media Contact:**

Argot Partners  
David Rosen  
(212) 600-1902  
[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)

**BAUDaX BIO**

Source: Baudax Bio, Inc.